Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
August 10 2023 - 8:50AM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, announced today
that it has retained the services of Clarivate™, a leading
global provider of information services including IP lifecycle
management solutions. Under terms of the agreement, Clarivate will
manage, maintain, and track the Company’s intellectual property
assets and technology rights, and serve as an advisor for strategic
IP and patent expansion in support of pipeline development.
Silo Pharma engages in the acquisition, licensing, and
development of intellectual property and technology rights from
leading universities and researchers, including the use of
psychedelic drugs. The Company’s IP-protected portfolio assets were
acquired through exclusive drug development collaborations
including a sponsored study agreement and a licensing option
agreement with Columbia University; a license and option agreement
and an investigator-sponsored study agreement with the University
of Maryland, Baltimore; a joint venture with Zylö Therapeutics,
Inc.; and a sponsored research agreement with the University of
California, San Francisco.
“Our new agreement with Clarivate gives us the opportunity to
step up our intellectual property and patent expansion efforts and
reinforce protection for our novel assets under development,” said
Eric Weisblum, Chief Executive Officer of Silo Pharma. “Clarivate’s
IP intelligence solutions will provide insights and
clarity to inform our pursuit of future opportunities.”
Silo Pharma currently holds 3 issued and provisional patents
with additional patent applications pending.
In 2023, year-to-date, Silo Pharma has been awarded 3 new
patents and one patent extension:
- U.S. Patent 16/825,371, covering SPU-21 as a method of
selectively targeting inflamed synovial tissue.
- U.S. Patent 11,622,948, covering the use of biomarkers in
determining efficacy of SPC-15 as a method of treatment for a
stress-induced affective disorder or stress-induced
psychopathology.
- U.S. Patent 11,491,120, covering SPC-15 in a method of treating
stress-induced affective disorders including anxiety and PTSD.
In addition, the Company has filed a provisional patent
application titled “Methods and Compositions for Pain Management.”
The action supports a planned Investigational New Drug (IND)
package submission to FDA for SP-26. Another provisional patent
application was filed for the use of its central nervous system
(CNS) homing peptides to treat Alzheimer's disease and the onset of
dementia.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company under takes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Apr 2024 to May 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From May 2023 to May 2024